Burger, J.P.W.; van Lochem, E.G.; Roovers, E.A.; Drenth, J.P.H.; Wahab, P.J.
Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial. Nutrients 2022, 14, 1771.
https://doi.org/10.3390/nu14091771
AMA Style
Burger JPW, van Lochem EG, Roovers EA, Drenth JPH, Wahab PJ.
Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial. Nutrients. 2022; 14(9):1771.
https://doi.org/10.3390/nu14091771
Chicago/Turabian Style
Burger, Jordy P. W., Ellen G. van Lochem, Elisabeth A. Roovers, Joost P. H. Drenth, and Peter J. Wahab.
2022. "Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial" Nutrients 14, no. 9: 1771.
https://doi.org/10.3390/nu14091771
APA Style
Burger, J. P. W., van Lochem, E. G., Roovers, E. A., Drenth, J. P. H., & Wahab, P. J.
(2022). Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial. Nutrients, 14(9), 1771.
https://doi.org/10.3390/nu14091771
